Inactive Instrument

Oncolix, Inc.

Equities

ONCX

US68236C1062

Biotechnology & Medical Research

Oncolix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2018

November 19, 2018 at 03:54 pm

Oncolix, Inc. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced net loss was USD 1.059 million compared to USD 803,186 a year ago. Basic loss per share was USD 0.01 compared to USD 0.009 a year ago. For the nine months, net loss was USD 5.980 million compared to USD 2.137 million a year ago. Basic loss per share was USD 0.065 compared to USD 0.027 a year ago.

Latest news about Oncolix, Inc.

Oncolix Announces Board Resignations	19-03-11	CI
Oncolix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2018	18-11-19	CI
Oncolix, Inc. announced that it has received $0.083 million in funding from PowerUp Lending Group, Ltd.	18-11-15	CI
Oncolix, Inc. Finalizes its License Agreement from IGL Pharma, Inc. for Novel, Clinical Stage Drug for the Treatment of Osteosarcoma	18-10-10	CI
Oncolix, Inc. Appoints Robert Niecestro as Member of its Regulatory Strategy, Scientific and Clinical Advisory Board	18-07-19	CI
Oncolix, Inc. Elects Sherry Grisewood as Director	18-06-29	CI
Oncolix Seeks Acquisitions	18-06-01	CI
Oncolix, Inc. announced that it has received $1.034699 million in funding from Mario Family Partners, Concordia Capital Partners, LLC, Northbridge Financial Services, Manchester Management Company, LLC, Pacific Capital Management, FirstFire Capital Management LLC	18-05-31	CI
Oncolix, Inc. Auditor Raises 'Going Concern' Doubt	18-03-13	CI
Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta™ Phase 1 Trial in Advanced Ovarian Cancer	18-01-08	CI
Oncolix, Inc Announces Appointment of John W. Holaday as Board of Directors	17-12-04	CI
Advanced Environmental Petroleum Producers, Inc. will Change its Ticker to ONCX from AEPP	17-11-29	CI
Oncolix, Inc. Reports Unaudited Earnings Results for the Three Months Ended March 31, 2017	17-11-24	CI
Oncolix, Inc Announces Appointment of Board of Directors	17-10-04	CI
Oncolix, Inc. Auditor Raises 'Going Concern' Doubt	17-08-08	CI
Oncolix, Inc. announced that it has received funding	17-08-06	CI
Oncolix, Inc. completed the acquisition of Advanced Environmental Petroleum Producers, Inc. in a reverse merger transaction.	17-08-02	CI
Oncolix, Inc. entered into a definitive agreement to acquire Advanced Environmental Petroleum Producers, Inc. in a reverse merger transaction.	17-07-23	CI
Oncolix, Inc. completed the acquisition of a 65.9% stake in Advanced Environmental Petroleum Producers, Inc. from New Opportunity Business Solutions, Inc. and Brian K. Kistler.	17-04-07	CI
Oncolix, Inc. agreed to acquire a 65.9% stake in Advanced Environmental Petroleum Producers, Inc. from New Opportunity Business Solutions, Inc. and Brian K. Kistler for $0.32 million.	17-03-07	CI
Oncolix, Inc. announced that it expects to receive funding	17-01-19	CI
Oncolix, Inc. announced that it has received $0.2 million in funding	16-12-30	CI
Advanced Environmental Petroleum Producers, Inc. announced that it expects to receive $0.2 million in funding	16-09-12	CI
Oncolix, Inc. announced that it has received $0.02225 million in funding	16-08-18	CI
Oncolix, Inc. announced that it has received $0.0375 million in funding	15-11-08	CI

Chart Oncolix, Inc.

Duration

Period

More charts

Company Profile

Oncolix, Inc., formerly Advanced Environmental Petroleum Producers Inc., is a clinical-stage biopharmaceutical company. The Company is primarily focused on the development of Prolanta, a biological drug for the treatment of cancer. The Company's initial focus is ovarian cancer, and commenced a Phase I clinical trial of Prolanta for the treatment of ovarian cancer. Prolanta is effective in the treatment of breast, uterine, prostate and other cancers. The Company's Prolanta is a genetically modified form of human prolactin, a hormone associated with various types of cancers. Prolanta is designed to bind to the prolactin receptor on cells to block the effects of human prolactin. Human prolactin has documented to cause cancer cell proliferation by interacting with cancer cells. The Company has conducted animal studies to determine the efficacy of Prolanta in treating breast and ovarian cancers.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.20%	126B
REGENERON PHARMACEUTICALS, INC.	+22.77%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.95%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.01%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+10.00%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+51.61%	14.08B

Bio Therapeutic Drugs